Japan formally approves nation’s first abortion pill
Until now, surgery was the only approved option for early-term abortions in Japan
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.Japan has approved the sale of an oral abortion pill for the first time, offering women an alternative to the surgical procedure, the nation’s health ministry has announced.
The move was hailed by medical experts as a major step for reproductive rights in the country, but insisted this was the “minimum” to have been done.
Women in early pregnancy across the country will now be able to access Mefeego – a treatment developed by the UK pharmaceutical company Linepharma International that can terminate a pregnancy of up to nine weeks of gestation.
The treatment is a two-drug combination. The first, mifepristone, blocks the hormone progesterone, without which the lining of the uterus breaks down, meaning the pregnancy cannot continue. The second, misoprostol, taken 36 to 48 hours later, causes the uterus to empty.
After four to six hours the lining of the womb breaks down, causing bleeding and loss of the pregnancy. It does not need surgery or an anaesthetic.
Until now, surgery was the only approved option for early-term abortions in Japan, but the method has been criticised for risking harm to the uterus.
Abdominal pain and bleeding are noted as possible side effects of Mefeego, meaning women who take the treatment must stay in a hospital until the abortion is confirmed by doctors.
Pharmaceutical companies and medical institutions are asked to give monthly reports to their local medical associations on the number of pills that have been sold and used.
The World Health Organisation (WHO) has designated Mefeego as an essential drug for abortion and has promoted it as a safe alternative.
The Mefeego pill pack is available in 80 countries, according to Linepharma International.
The Ministry of Health, Labour and Welfare approved it under the country’s maternal health law and the pill has drawn considerable interest in Japan over its possible side effects and price.
Mefeego’s manufacturing and marketing was approved by a health ministry panel last week after the ministry received around 12,000 public comments.
There were 126,174 abortions in Japan in fiscal 2021, according to the health ministry.
Kumi Tsukahara, director of the Reproductive Health Rights Literacy Institute, said: “Being able to control one’s own pregnancy is already the minimum requirement for gender equality.
“Although this discussion is on medicine, we must not lose sight of how this is a human rights issue.”
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments